22 June 2023  
EMA/CHMP/284978/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
COMIRNATY 
COVID-19 mRNA Vaccine (nucleoside modified) 
On 22 June 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Comirnaty. The marketing authorisation holder for this medicinal product is BioNTech Manufacturing 
GmbH. 
The CHMP adopted an extension to an existing indication to include the use of Comirnaty 
Original/Omicron BA.4-5 (15/15 micrograms) in individuals 12 years of age and older who have not 
previously received at least a primary vaccination course against COVID-19. For information, the full 
indication for Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose will be as follows2:  
Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection is indicated 
for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of 
age and older who have previously received at least a primary vaccination course against COVID-
19 (see sections 4.2 and 5.1).  
The use of this vaccine should be in accordance with official recommendations. 
The CHMP also adopted an extension to an existing indication to include the use of Comirnaty 
Original/Omicron BA.4-5 (5/5 micrograms)/dose in children aged 5 to 11 years who have not previously 
received at least a primary vaccination course against COVID-19. For information, the full indication for 
Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose will be as follows2: 
Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose concentrate for dispersion for 
injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in 
children aged 5 to 11 years who have previously received at least a primary vaccination course 
against COVID-19 (see sections 4.2 and 5.1).  
The use of this vaccine should be in accordance with official recommendations. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 Deleted text in strikethrough font, new text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
The CHMP also adopted an extension to an existing indication to include the use of Comirnaty 
Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose in infants and children aged 6 months to 4 years. 
For information, the full indication for Comirnaty Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose will 
be as follows2:  
Comirnaty Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose concentrate for 
dispersion for injection is indicated for active immunisation to prevent COVID-19 
caused by SARS-CoV-2, in infants and children aged 6 months to 4 years.  
The use of this vaccine should be in accordance with official recommendations. 
For information, the indications for other presentations of Comirnaty are provided in the summary of 
product characteristics (SmPC). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
COMIRNATY  
EMA/CHMP/284978/2023 
Page 2/2 
 
 
 
 
 
